Akebia Therapeutics, Inc.
AKBA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001517022
In the last 90 days, Akebia Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 170 institutions reported holding it in 13F filings for Q2 2026, worth $123.2M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Akebia Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $62.2K in total
- Insiders trading
- 1
- Net value
- −$62.2K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Akebia Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Butler John P. | CEO and President | 3,718,564 | Aug 10, 2026 | 4 |
| Ostrowski Erik | SVP, CFO, CBO & Treasurer | 616,616 | Jul 1, 2026 | 3 |
| Zumwalt Leanne M | Director | 145,100 | Jun 22, 2026 | 1 |
| Rogers Michael W | Director | 197,429 | Jun 22, 2026 | 1 |
| Adams Adrian | Director | 236,200 | Jun 22, 2026 | 1 |
| Smith Cynthia | Director | 196,633 | Jun 22, 2026 | 1 |
| Wolf Myles | Director | 169,081 | Jun 22, 2026 | 1 |
| Frieson Ron | Director | 165,200 | Jun 22, 2026 | 1 |
| Vickers Philip J. | Director | – | Apr 3, 2026 | 1 |
| Burke Steven Keith | SVP, Chief Medical Officer | 948,432 | Feb 4, 2026 | 2 |
| Grund Nicholas | Chief Commercial Officer | 561,750 | Feb 4, 2026 | 2 |
| Malabre Richard C | SVP, Chief Accounting Officer | 299,390 | Feb 4, 2026 | 2 |
| Rucci Carolyn M. | SVP, Chief Legal Officer | 588,378 | Feb 4, 2026 | 2 |
| Gilman Steven C | Director | 152,830 | Jun 11, 2025 | 0 |
| Hadas Nicole R. | SVP, Chief Legal Officer | 651,243 | May 14, 2024 | 0 |
| Dahan Michel | SVP, Chief Operating Officer | 672,092 | May 14, 2024 | 0 |
| Snow Ellen | SVP, CFO and Treasurer | 519,300 | Feb 2, 2024 | 0 |
| Spellman David A | SVP, CFO and Treasurer | 446,483 | May 18, 2023 | 0 |
| Cotreau Violetta | SVP, Chief Accounting Officer | 219,954 | May 16, 2022 | 0 |
| Faulkingham Dell | SVP, CCO | 173,841 | Mar 2, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 2022 (view filing) | Feb 28-Mar 1 | 2 days | Faulkingham DellSVP, CCO | SSale | −13.2K | $2.16 | −$28.5K | −7.0%173.8K after | 3 lots |
| Mar 2, 2022 (view filing) | Feb 28-Mar 1 | 2 days | Hadas Nicole R.SVP, Chief Legal Officer | SSale | −21.1K | $2.16 | −$45.6K | −6.5%304.2K after | 4 lots |
| Mar 2, 2022 (view filing) | Feb 28-Mar 1 | 2 days | Spellman David ASVP, CFO and Treasurer | SSale | −8.20K | $2.15 | −$17.7K | −6.0%128.6K after | 2 lots |
| Jan 5, 2022 (view filing) | Jan 3 | 2 days | Cotreau ViolettaSVP, Chief Accounting Officer | SSale | −5.83K | $2.29 | −$13.4K | −15.0%33.1K after | |
| Sep 2, 2021 (view filing) | Aug 31 | 2 days | Burke Steven KeithSVP, Chief Medical Officer | SSale | −1.04K | $2.83 | −$2.95K | −0.6%171.2K after |